Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
Annual filings (FY) with consensus forward estimates (hatched)
1255 daily bars · split adjusted
Daily · Wilder smoothing
Classic floor pivots from 2026-10-23
Computed from daily OHLCV bars
| Indicator | Value | Type | Action |
|---|---|---|---|
| RSI (14) | 50.86 | Oscillator | Neutral |
| Stochastic %K (14, 3, 3) | 32.37 | Oscillator | Neutral |
| Williams %R (14) | -73.38 | Oscillator | Neutral |
| MACD (12, 26, 9) | 0.27 (Hist 0.00) | Oscillator | Strong Buy |
| Average Directional Index (14) | 38.96 (+DI 28.7 / -DI 17.3) | Trend | Strong Buy |
| EMA 20 | 5.52 | MA | Sell |
| SMA 20 | 5.36 | MA | Buy |
| EMA 50 | 4.99 | MA | Strong Buy |
| SMA 50 | 4.84 | MA | Strong Buy |
| SMA 200 | 4.53 | MA | Strong Buy |
Current price $5.46
Latest analyst grade actions
Stock news · updated daily
Lilly to showcase advances across its oncology pipeline at the 2026 European Society for Medical Oncology (ESMO) CongressPR NewswireINDIANAPOLIS, Oct. 18, 2026F
Lilly's EloraTZP (combination of eloralintide and tirzepatide) delivered greater weight loss and A1C reduction vs. tirzepatide 15 mg in adults with obesity and
Lilly's Foundayo (orforglipron) 17.2 mg showed greater weight loss and A1C reduction than oral semaglutide 25 mg among adults with type 2 diabetes in a new indi
Reported EPS vs. consensus estimate
| Report date | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|
| Jul 2, 2026 | — | -0.02 | — | — |
| Apr 8, 2026 | — | -0.24 | — | — |
| Jul 9, 2025 | — | -1.84 | — | -$20.48M |
| Jul 30, 2024 | — | -1.14 | — | — |
| Apr 16, 2024 | — | -0.30 | — | -$1.99M |
FY2024 · 10-K disclosure
FY2025 · 10-K disclosure
SEC EDGAR filings · last 12 months
| Form | Filed | Accepted | Document |
|---|---|---|---|
| 6-K | Aug 12, 2026 | 2026-08-12 16:16:49 | View |
| 20-F | Apr 2, 2026 | 2026-04-02 17:16:01 | View |
| 3 | Mar 31, 2026 | 2026-03-31 12:42:52 | View |
| 3 | Mar 31, 2026 | 2026-03-31 12:42:38 | View |
| 3 | Mar 31, 2026 | 2026-03-31 12:42:22 | View |
| 3 | Mar 31, 2026 | 2026-03-31 12:42:05 | View |
| 3 | Mar 31, 2026 | 2026-03-31 12:41:44 | View |
| 6-K | Jan 29, 2026 | 2026-01-29 16:30:42 | View |
| 6-K | Dec 11, 2025 | 2025-12-11 08:30:29 | View |
| 6-K | Oct 28, 2025 | 2025-10-28 14:46:06 | View |
Proxy statement (DEF 14A) disclosures
Free float vs. closely held shares
13F institutional holdings are not available in the current data plan.
SEC Form 4 filings
| Date | Insider | Role | Type | Shares @ price | Value |
|---|---|---|---|---|---|
| Mar 18, 26 | Ren Xiaofei | director: | 0 | — | |
| Mar 18, 26 |
| Wen Xiangdong |
| director, officer: Chairman, CEO |
| 0 |
| — |
| Mar 18, 26 | Wen Xiangdong | director, officer: Chairman, CEO | 0 | — |
| Mar 18, 26 | Meng Qingshun | director: | 0 | — |
| Mar 18, 26 | Kong Min | director, officer: Chief Financial Officer | 0 | — |
| Mar 18, 26 | Fu Dan | director: | 0 | — |
TTM vs. 5-year historical average (annual ratios)
| Metric | MTC | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | -21.3x | -7.2x · sector 20.4x | Discount |
| Forward P/E | — | — | n/a |
| Price / Book | 41.9x | 5.4x | Elevated |
| Price / Sales | — | 70.4x | Discount |
| EV / EBITDA | -147.9x | -12.6x | Elevated |
| Return on equity | -81.7% | — | Weak |
| Gross margin | 0.0% | 76.5% | Below hist. |
| Debt / Equity | 0.26 | 0.38 | Conservative |
| Piotroski / Altman Z | 4/9 | Z 77.89 | Safe zone |
Discounted cash flow model